Sains Malaysiana 53(11)(2024): 3683-3693

http://doi.org/10.17576/jsm-2024-5311-12

 

Sensitive Detection of PIK3CA Exon 20 H1047R Breast Cancer Based on Low-Cost Intercalary Dye SYBR Green I Real-Time qPCR Assay

(Pengesanan Sensitif PIK3CA Exon 20 H1047R Kanser Payudara Berdasarkan Pewarna Interkalari Kos Rendah SYBR Green I Ujian Asai qPCR Masa Nyata)

 

DESRIANI¹, AZAMRIS², PRIMARIADEWI RUSTAMADJI³, INHERNI MARTI ABNA⁴, IRSYAD IBADURRAHMAN¹, ASRUL MUHAMMAD FUAD¹, DINI NURDIANI¹, YULIAWATI YULIAWATI¹, NURULIAWATY UTAMI¹, NENG HERAWATI¹, NAJMIATUL FITRIA⁵ & MUHAMMAD ALI WARISMAN¹

 

¹Research Center for Genetic Engineering, Research Organization for Life Sciences and Environment, National Research and Innovation Agency. 16911 Jl. Raya Km 46 Cibinong, Kabupaten Bogor, Jawa Barat, Indonesia

²Division of Surgical Oncology, Medical School of Andalas University, 25127 Jl. Perintis Kemerdekaan no 94, Padang, Sumatera Barat, Indonesia

³Division of Anatomy Pathology, Faculty of Medicine, Universitas Indonesia, 10430 Jl. Salemba Raya No 6, Kenari, Kec Senen, Jakarta, Indonesia

⁴Pharmacy Study Program, Faculty of Health Science, Esa Unggul University, 11510 Jl. Arjuna Utara No 9, Duri Kepa, Jakarta, Indonesia

⁵Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Andalas University, 25175 Limau Manis, Pauh, Padang, Sumatera Barat, Indonesia

 

Received: 21 March 2024/Accepted: 4 September 2024

 

Abstract

Breast cancer is associated with an excessive function of somatic mutation in phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit α (PIK3CA), specifically in exon 9 and 20 hotspots. Exon 20, which contains H1047R, has more potential for an oncogenic mutation than exon 9. Detection of PIK3CA/H1047R mutation has also been reported for molecular diagnosis and therapeutic application. Sensitive methods are required because mutants are mostly present at low levels in a mixture with the wild type. Therefore, this study aimed to explore the development of a low-cost and sensitive PIK3CA exon 20 H1047R detection method using intercalary dye real-time qPCR (quantitative polymerase chain reaction), SYBR Green I. The method was primer design, formulation, specificity, limit of detection, reproducibility, repeatability, and genotyping of 15 DNA (deoxyribonucleic acid)-frozen tissue patient samples, which were further confirmed by PCR sequencing for validation. DNA primer proportion formulations were 0.25 µM PIK3CA exon 20 (WT), 0.65 µM PIK3CA exon 20 H1047 (MT), and 0.2 µM reverse primer in 10 μl total volume. The results showed that compared to the gold standard genotyping PCR sequencing (6.6-20%), the developed method had a higher sensitivity of 5%. The coefficients of intra- and inter-variability were between 0.01-0.19%, suggesting the developed method was repeatable and reproducible with a low mean pipetting error. Genotyping of 15 DNA breast cancer patient samples showed a wild-type genotype, which was in 100% agreement with the PCR sequencing result. The developed method showed sensitive, reproducible, and repeatable results,  potentially applicable in prognosis and therapeutic predictions.

 

Keywords: Breast cancer; Exon 20; H1047R; mutation; PIK3CA

 

Abstrak

Kanser payudara dikaitkan dengan fungsi berlebihan mutasi somatik dalam subunit pemangkin fosfatidilinositol-4,5-bisfosfat 3-kinase α (PIK3CA), khususnya di exon 9 dan 20 titik panas. Exon 20 yang mengandungi H1047R lebih berpotensi untuk mutasi onkogenik berbanding exon 9. Pengesanan mutasi PIK3CA/H1047R juga telah dilaporkan untuk diagnosis molekul dan aplikasi terapeutik. Kaedah sensitif diperlukan kerana mutan kebanyakannya terdapat pada tahap rendah dalam campuran dengan jenis liar. Oleh itu, kajian ini bertujuan untuk meneroka pembangunan kaedah pengesanan PIK3CA exon 20 H1047R yang kos rendah dan sensitif menggunakan qPCR masa nyata pewarna interkalari (tindak balas rantai polimerase kuantitatif), SYBR Green I. Kaedahnya ialah reka bentuk primer, formulasi, kekhususan, had pengesanan, kebolehasilan, kebolehulangan dan genotaip 15 sampel pesakit tisu DNA (asid deoksiribonukleik)-beku, yang selanjutnya disahkan oleh penjujukan PCR untuk pengesahan. Formulasi perkadaran primer DNA ialah 0.25 µM PIK3CA exon 20 (WT), 0.65 µM PIK3CA exon 20 H1047 (MT) dan 0.2 µM primer songsang dalam 10 μL jumlah isi padu. Keputusan menunjukkan bahawa berbanding dengan penjujukan PCR genotaip piawaian emas (6.6-20%), kaedah yang dibangunkan mempunyai kepekaan yang lebih tinggi sebanyak 5%. Pekali intra-dan inter-kevariabelan adalah antara 0.01-0.19% menunjukkan kaedah yang dibangunkan boleh diulang dan boleh dihasilkan semula dengan ralat pipet min yang rendah. Genotaip 15 sampel pesakit kanser payudara DNA menunjukkan genotaip jenis liar yang 100% bersetuju dengan hasil penjujukan PCR. Kaedah yang dibangunkan menunjukkan keputusan yang sensitif, boleh dihasilkan semula dan boleh diulang, berpotensi digunakan dalam ramalan prognosis dan terapeutik.

 

Kata kunci: Exon 20; H1047R; kanser payudara; mutasi; PIK3CA

 

REFERENCES

Ahmad, F., Badwe, A., Verma, G., Bhatia, S. & Das, B.R. 2016. Molecular evaluation of PIK3CA gene mutation in breast cancer: Determination of frequency, distribution pattern and its association with clinicopathological findings in Indian patients. Medical Oncology 33: 74. DOI: 10.1007/s12032-016-0788-y

Alvarez-Garcia, V., Bartos, C., Keraite, I., Trivedi, U., Brennan, P.M., Kersaudy-Kerhoas, M., Gharbi, K., Oikonomidou, O. & Leslie, N.R. 2018. A simple and robust real-time QPCR method for the detection of PIK3CA mutations. Scientific Reports 8: 4290. DOI: 10.1038/s41598-018-22473-9

Appelt, S., Aly, S.S., Tonooka, K., Glenn, K., Xue, Z., Lehenbauer, T.W. & Marco, M.L. 2019. Development and comparison of loop-mediated isothermal amplification and quantitative polymerase chain reaction assays for the detection of Mycoplasma bovis in milk. Journal of Dairy Science 102(3): P1985-1996. http://dx.doi.org/10.3168/jds.2018-15306

Arsenic, R., Lehmann, A., Budczies, J., Koch, I., Prinzler, J., Kleine-Tebbe, A., Schewe, C., Loibl, S., Dietel, M. & Denkert, C. 2014. Analysis of PIK3CA mutations in breast cancer subtypes. Applied Immunohistochemistry and Molecular Morphology 22(1): 50-56. DOI: 10.1097/PDM.0b013e318297afea

Borkowska, E.M., Nska, M.B., Kowalczyk, M. & Pietruszewska, W. 2021. Detection of PIK3CA gene mutation in head and neck squamous cell carcinoma using droplet digital PCR and RT-QPCR. Biomolecules 11(6): 818.

Bustin, S.A., Benes, V., Garson, J.A., Hellemans, J., Huggett, J., Kubista, M., Mueller, R., Nolan, T., Pfaffl, M.W., Shipley, G.L., Vandesompele, J. & Wittwer, C.T. 2009. The MIQE guidelines: Minimum Information for publication of Quantitative real-time PCR Experiments. Clinical Chemistry 55(4): 611-622. DOI: 10.1373/clinchem.2008.112797

Campbell, I.G., Russell, S.E., Choong, D.Y.H., Montgomery, K.G., Ciavarella, M.L., Hooi, C.S.F., Cristiano, B.E., Pearson, R.B. & Phillips, W.A. 2004. Mutation of the PIK3CA gene in ovarian and breast cancer Cancer Research 64(21): 7678-7681. DOI: 10.1158/0008-5472.CAN-04-2933

Cao, G., Chen, X., Deng, Y., Nie, F., Liu, Y., Wang, G., Huo, D. & Hou, C. 2021. Single-nucleotide variant of PIK3CA^H1047R gene assay by CRISPR/Cas12a combined with rolling circle amplification. Analytica Chimica Acta 1182: 338943. https://doi.org/10.1016/j.aca.2021.338943

Chen, L., Yang, L., Yao, L., Kuang, X.Y., Zuo, W.J., Li, S., Qiao, F., Liu, Y.R., Cao, Z.G., Zhou, S.L., Zhou, X.Y., Yang, W.T., Shi, J.X., Huang, W., Hu, X. & Shao, Z.M. 2018. Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients. Nature Communications 9(1): 1357. http://dx.doi.org/10.1038/s41467-018-03867-9

Daneshmand, M., Hanson, J.E.L., Nabavi, M., Hilton, J.F., Vandermeer, L., Kanji, F., Dent, S.F., Clemons, M. & Lorimer, I.A.J. 2012. Detection of PIK3CA mutations in breast cancer bone metastases. ISRN Oncology 2012: 492578. DOI: 10.5402/2012/492578

Deng, Y., Cao, G., Chen, X., Yang, M., Huo, D. & Hou, C. 2021. Ultrasensitive detection of gene-PIK3CA^H1047R mutation based on cascaded strand displacement amplification and trans-cleavage ability of CRISPR/Cas12a. Talanta 232: 122415. https://doi.org/10.1016/j.talanta.2021.122415

Desriani & Al-Ahwani, F. 2018. The sensitivity and efficacy method of PIK3CA exon 9 E545A as a high diagnostic accuracy in breast cancer. Journal of Genetic Engineering and Biotechnology 16(1): 71-76. DOI: 10.1016/j.jgeb.2017.10.002

Desriani, Azamris, Ghaissani, S.S., Kinanti, S.R., Warisman, M.A. & Fitria, N. 2021. Design and characterization of a SYBR green i-based melting curve method for investigation of HER2I655V polymorphism in breast cancer. Journal of Genetic Engineering and Biotechnology 19: 6. DOI: 10.1186/s43141-020-00108-9

Dirican, E., Kaya, Z., Gullu, G., Peker, I., Ozmen, T., Gulluoglu, B.M., Kaya, H., Ozer, A. & Akkiprik, M. 2014. Detection of PIK3CA gene mutations with HRM analysis and association with IGFBP-5 expression levels in breast cancer. Asian Pacific Journal of Cancer Prevention 15(21): 9327-9333. DOI: 10.7314/APJCP.2014.15.21.9327

Ghalamkari, S., Khosravian, F., Mianesaz, H., Kazemi, M., Behjati, M., Hakimian, S.M. & Salehi, M. 2019. A comparison between full-COLD PCR/HRM and PCR sequencing for detection of mutations in exon 9 of PIK3CA in breast cancer patients. Applied Biochemistry and Biotechnology 187(3): 975-983. DOI: 10.1007/s12010-018-2859-3

Gkeka, P., Evangelidis, T., Pavlaki, M., Lazani, V., Christoforidis, S., Agianian, B. & Cournia, Z. 2014. Investigating the structure and dynamics of the PIK3CA wild-type and H1047R oncogenic mutant. PLoS Computational Biology 10(10): e1003895. DOI: 10.1371/journal.pcbi.1003895

Guo, S., Loibl, S., von Minckwitz, G., Darb-Esfahani, S., Lederer, B. & Denkert, C. 2020. PIK3CA H1047R mutation associated with a lower pathological complete response rate in triple-negative breast cancer patients treated with anthracycline-taxane - based neoadjuvant chemotherapy.  Cancer Research and Treatment 52(3): 689-696.

Han, X., Beck, K., Bürgmann, H., Frey, B., Stierli, B. & Frossard, A. 2023. Synthetic oligonucleotides as quantitative PCR standards for quantifying microbial genes. Frontiers in Microbiology 14: 1279041. DOI: 10.3389/fmicb.2023.1279041

Hanker, A.B., Pfefferle, A.D., Balko, J.M., Kuba, M.G., Young, C.D., Sánchez, V., Sutton, C.R., Cheng, H., Perou, C.M., Zhao, J.J., Cook, R.S. & Arteaga, C.L. 2013. Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies. Proceedings of the National Academy of Sciences of the United States of America 110(35): 14372-14377. DOI: 10.1073/pnas.1303204110

Ihle, M.A., Fassunke, J., König, K., Grünewald, I., Schlaak, M., Kreuzberg, N., Tietze, L., Schildhaus, H.U., Büttner, R. & Merkelbach-Bruse, S. 2014. Comparison of high-resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations. BMC Cancer 14: 13. DOI: 10.1186/1471-2407-14-13

Kalofonou, M., Malpartida-Cardenas, K., Alexandrou, G., Rodriguez-Manzano, J., Yu, L.S., Miscourides, N., Allsopp, R., Gleason, K.L.T., Goddard, K., Fernandez-Garcia, D., Page, K., Georgiou, P., Ali, S., Coombes, R.C., Shaw, J. &  Toumazou, C. 2020. A novel hotspot specific isothermal amplification method for detection of the common PIK3CA p.H1047R breast cancer mutation. Scientific Reports 10: 4553. DOI: 10.1038/s41598-020-60852-3

Kang, S., Bader, A.G. & Vogt, P.K. 2005. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. PNAS 102(3): 802-807.

Lai, Y.L., Mau, B.L., Cheng, W.H., Chen, H.M., Chiu, H.H. & Tzen, C.Y. 2008. PIK3CA exon 20 mutation is independently associated with a poor prognosis in breast cancer patients. Annals of Surgical Oncology 15(4): 1064-1069. DOI: 10.1245/s10434-007-9751-7&

Leong, V.C., Faizal, M., Pooi, P., Atmadini, M., Alif, Y. & Fong, H. 2008. PIK3CA gene mutations in breast carcinoma in Malaysian patients. Cancer Genet Cytogenet 187(2): 74-79. DOI: 10.1016/j.cancergencyto.2008.07.005

Leontiadou, H., Galdadas, I., Athanasiou, C. & Cournia, Z. 2018. Insights into the mechanism of the PIK3CA E545K activating mutation using MD simulations. Scientific Reports 8: 15544. DOI: 10.1038/s41598-018-27044-6

Li, W.M., Hu, T.T., Zhou, L.L., Feng, Y.M., Wang, Y.Y. & Fang, J. 2016. Highly sensitive detection of the PIK3CA^H1047R mutation in colorectal cancer using a novel PCR-RFLP method. BMC Cancer 16: 454. DOI: 10.1186/s12885-016-2493-9

Liu, J., Huang, S., Sun, M., Liu, S., Liu, Y., Wang, W., Zhang, X., Wang, H. & Hua, W. 2012. An improved allele-specific PCR primer design method for SNP marker analysis and its application. Plant Methods 8(1): 34. DOI: 10.1186/1746-4811-8-34

Meyer, D.S., Koren, S., Leroy, C., Brinkhaus, H., Müller, U., Klebba, I., Müller, M., Cardiff, R.D. & Bentires-Alj, M. 2013. Expression of PIK3CA mutant E545K in the mammary gland induces heterogeneous tumors but is less potent than mutant H1047R. Oncogenesis 2(9): e74. DOI: 10.1038/oncsis.2013.38

Mote, R.D., Laxmikant, V.S., Singh, S.B., Tiwari, M., Singh, H., Srivastava, J., Tripathi, V., Seshadri, V., Majumdar, A. & Subramanyam, D. 2021. A cost-effective and efficient approach for generating and assembling reagents for conducting real-time PCR. Journal of Biosciences 46(4): 109. DOI: 10.1007/s12038-021-00231-w

Paudel, D., Jarman, R., Limkittikul, K., Klungthong, C., Chamnanchanunt, S., Nisalak, A., Gibbons, R. & Chokejindachai, W. 2011. Comparison of real-time SYBR green dengue assay with real-time Taqman RT-PCR dengue assay and the conventional nested PCR for diagnosis of primary and secondary dengue infection. North American Journal of Medical Sciences 3(10): 478-485. DOI: 10.4297/najms.2011.3478

Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S.M., Riggins, G.J., Willson, J.K., Markowitz, S., Kinzler, K.W., Vogelstein, B. & Velculescu, V.E. 2004. High frequency of mutations of the PIK3CA gene in human cancers. Science 304(5670): 554. DOI: 10.1126/science.1096502

Shimoi, T., Hamada, A., Yamagishi, M., Hirai, M., Yoshida, M., Nishikawa, T., Sudo, K., Shimomura, A., Noguchi, E., Yunokawa, M., Yonemori, K., Shimizu, C., Kinoshita, T., Fukuda, T., Fujiwara, Y. & Tamura, K. 2018. PIK3CA mutation profiling in patients with breast cancer, using a highly sensitive detection system. Cancer Science 109(8): 2558-2566. DOI: 10.1111/cas.13696

Wang, J., Chuang, K., Ahluwalia, M., Patel, S., Umblas, M., Mirel, D., Higuchi, R. & Germer, S. 2005. High-throughput SNP genotyping by single-tube PCR with T_m-shift primers. BioTechniques 39(6): 885-893. DOI: 10.2144/000112028

Wang, Y., Yang, K., Bai, C., Yin, D., Li, G., Qi, K., Wang, G. & Li, Y. 2017. Development of a SYBR Green I real-time PCR for the detection of the orf virus. AMB Express 7(1):  1-6. DOI: 10.1186/s13568-016-0322-9

Yi, Z., Ma, F., Liu, B., Guan, X., Li, L., Li, C., Qian, H. & Xu, B. 2019. Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study. BMC Cancer 19(1): 442.

Yuan, W., Stawiski, E., Janakiraman, V., Chan, E., Durinck, S., Edgar, K.A., Kljavin, N.M., Rivers, C.S., Gnad, F., Roose-Girma, M., Haverty, P.M., Fedorowicz, G., Heldens, S., Soriano, R.H., Zhang, Z., Wallin, J.J., Johnson, L., Merchant, M., Modrusan, Z., Stern, H.M. & Seshagiri, S. 2013. Conditional activation of PIK3CA^H1047R in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations. Oncogene 32(3): 318-326. DOI: 10.1038/onc.2012.53

Zhao, L. & Vogt, P.K. 2008. Helical domain and kinase domain mutations in P110α of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. PNAS 105(7): 2652-2657.

Zheng, W., Jiang, L., Lei, Q., Yang, J., Gao, X., Wang, W., Zhang, Y., Kong, T., Chen, Q. & Li, G. 2019. Development and validation of quantitative real-time PCR for the detection of residual CHO host cell DNA and optimization of sample pretreatment method in biopharmaceutical products. Biological Procedures Online 21: 17. DOI: 10.1186/s12575-019-0105-1

 

*Corresponding author; email: desr001@brin.go.id